ENGOT EN20
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 TRIAL OF MAINTENANCE WITH SELINEXOR/ PLACEBO AFTER COMBINATION CHEMOTHERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Study Phase: Phase 3
Principal Investigator: Dr Karen Cadoo
Further information